Farmaceutické společnosti by mohly nadále patentovat a prodávat své výrobky tak jako dosud. Anebo by mohly svůj nový lék zaregistrovat u Fondu vlivu na zdraví, který by stanovil nízkou cenu, založenou na výrobních nákladech léku.
The fund would not replace existing patent laws, but would offer an alternative to them. Pharmaceutical companies could continue to patent and sell their products as they do now.  Alternatively, they could register a new drug with the Heath Impact Fund, which would set a low price based on the drug’s manufacturing cost.